Revvity The Alphalisa® Immunoassay Kit For Human

Revvity Formats: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Our 100 assay point kit allows you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Revvity AlphaLISA features: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

No-wash steps, no separation stepsELISA alternative technologySensitive detectionBroad sample compatibilitySmall sample volumeResults in less than 3 hoursHalf the time of an ELISA assay

Revvity AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Cluster of differentiation 70 (CD70), also known as CD27L or TNFSF7, is a type II transmembrane receptor protein expressed on activated T and B cells. It binds to CD27 on mature T-cells and a subset of thymocytes. Ligation of CD70 results in the proliferation of costimulated T cells. CD70 expression has been shown to be upregulated in range of lymphomas. Treatment with anti-CD70 antibodies has been introduced as a possible treatment for CD70+ tumors. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)